Contracts › 75N95025F00002
75N95025F00002: Data and Statistical Analysis for Glp-1 As an Adjunct to Buprenorphine. May 21, 2025 - February 29, 2028. N01DA-22-2253. Task Order No. 75N95025F00002 (TO26).
Awarded to The Emmes Company, Llc by National Institutes of Health (NIH).
$1.7Mobligated
$1.7Mpotential value
29 February 2028current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N95025F00002 |
|---|---|
| Vehicle | 75N95022D00017 |
| Awardee | The Emmes Company, Llc |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIDA |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN11 Health R&D Services; Health Care Services; Basic Research |
| Place of performance | MD |
| Period of performance | 21 May 2025 to 29 February 2028 |
| Potential end | 29 February 2028 |
| Estimated recompete solicitation | ~Q3 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record